FDA Approves Perioperative OPDIVO Plus Chemotherapy for Resectable NSCLC
The FDA has granted approval to Bristol Myers Squibb’s OPDIVO (nivolumab) for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC), specifically targeting tumors that are 4 cm or larger or node-positive and have no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. The new regimen combines neoadjuvant OPDIVO with platinum-doublet chemotherapy, followed by single-agent OPDIVO as an adjuvant treatment after surgery. This innovative approach, known as perioperative therapy, aims to improve outcomes for patients...
